Core Viewpoint - 莱伯泰科 reported a decline in both revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved total operating revenue of 285 million yuan, representing a year-on-year decrease of 8.43% [1] - The net profit attributable to shareholders was 32.55 million yuan, down 7.26% year-on-year [1] - Basic earnings per share were reported at 0.49 yuan [1]

Financial Performance - The company's revenue for Q3 2025 was ¥92,908,661.34, a decrease of 4.22% compared to the same period last year[2] - Total profit for the quarter was ¥13,260,810.45, reflecting an increase of 6.73% year-over-year[2] - Net profit attributable to shareholders was ¥11,453,748.67, up by 1.76% from the previous year[2] - Total operating revenue for the first three quarters of 2025 was CNY 284,872,833.06, a decrease of 8.5% compared to CNY 311,093,406.06 in the same period of 2024[18] - Net profit for the first three quarters of 2025 was CNY 32,546,867.25, a decline of 7.2% from CNY 35,096,522.16 in 2024[19] - Earnings per share for the first three quarters of 2025 was CNY 0.49, compared to CNY 0.53 in the same period of 2024[20] Cash Flow - The net cash flow from operating activities for the quarter was ¥10,429,408.97, a significant increase of 866.18% compared to the same period last year[2] - Net cash flow from operating activities was 2,583,396.37, a significant improvement from a negative cash flow of -3,051,848.65 in the previous period[22] - Total cash inflow from investment activities reached 1,035,641,465.80, compared to 901,770,270.89 in the prior period, indicating a growth of approximately 14.8%[22] - Cash outflow for investment activities was 1,033,124,451.17, up from 964,282,001.85, reflecting an increase of about 7.1%[22] - Net cash flow from investment activities was 2,517,014.63, a recovery from a negative cash flow of -62,511,730.96 in the previous period[22] - Cash received from tax refunds was 1,405,361.02, an increase from 1,165,909.27 in the previous period[22] - Cash received from other operating activities was 8,047,596.89, down from 14,536,511.58, indicating a decline of approximately 44.7%[22] - Cash paid for employee compensation was 91,718,610.65, a decrease from 97,099,560.70, reflecting a reduction of about 5.5%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥909,209,199.94, down 4.87% from the end of the previous year[3] - Current assets totaled RMB 733,318,726.56, down from RMB 767,512,121.41, indicating a decrease of about 4.46%[14] - Total liabilities decreased to RMB 101,674,755.51 from RMB 133,659,707.59, a reduction of about 24.0%[15] - Total liabilities decreased from CNY 138,123,645.32 in 2024 to CNY 105,036,189.12 in 2025, a reduction of approximately 23.9%[16] - Total equity attributable to shareholders decreased from CNY 817,588,631.13 in 2024 to CNY 804,173,010.82 in 2025, a decline of about 1.6%[16] Research and Development - Research and development expenses totaled ¥11,700,309.23, accounting for 12.59% of revenue, a decrease of 0.84 percentage points year-over-year[3] - Research and development expenses for the first three quarters of 2025 were CNY 35,316,884.16, down 6.5% from CNY 37,984,443.96 in 2024[19] Shareholder Information - The company held 674,222 shares in its repurchase account, accounting for 1.00% of the total share capital[12] - The top shareholder, Beijing LabTech Consulting Co., Ltd., holds 32.84% of the shares, while LabTech Holdings, Inc. holds 23.90%[11] Other Financial Metrics - The weighted average return on equity was 1.43%, an increase of 0.04 percentage points compared to the previous year[3] - Non-recurring gains and losses amounted to ¥2,805,474.93 for the quarter[6] - Other comprehensive income after tax for the first three quarters of 2025 was CNY -2,232,709.20, compared to CNY -1,072,568.64 in 2024[20] - Deferred income tax liabilities increased from CNY 997,501.46 in 2024 to CNY 1,208,474.28 in 2025, an increase of approximately 21.1%[16] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may impact financial reporting[24]

Core Insights - The article presents a compilation of high-paying job opportunities in the laboratory instrument sector, highlighting various positions and their requirements [3][4][5][6][8][10][11][12][13][15][17]. Job Opportunities - **Position: Sales Engineer at Pano** Salary: 8k-12k, 13 months salary Requirements: Background in science and engineering, good communication skills, and experience in laboratory sales preferred [3]. - **Position: Senior Application Engineer at LabTech** Salary: 20k-30k, 12 months salary Responsibilities include supporting ICPMS applications, pre-sales support, and market activities [4]. - **Position: Sales Representative at Shimadzu** Salary: Negotiable Requirements: College degree, industry experience preferred, and strong team and service awareness [5]. - **Position: Instrument Sales at Agilent** Location: Zhejiang, Salary: Negotiable Requirements: Bachelor's degree in relevant fields and over three years of sales experience in laboratory products [6][7]. - **Position: Vice President of Marketing at Fujian Jiupu** Salary: 30k-35k, 14 months salary Requirements: Over 10 years of sales management experience in laboratory instruments and strong marketing strategy skills [8]. - **Position: Sales Engineer (Material Characterization) at Anton Paar** Salary: Negotiable Requirements: Knowledge of relevant instruments and at least two years of industry experience [10]. - **Position: Market Engineer for Electron Microscopy at Hitachi** Salary: 10k-30k, 12 months salary Requirements: Master's or PhD in science or engineering and over two years of relevant experience [11][12]. - **Position: Testing Engineer at Xinghao Electronics** Salary: 6k-10k, 12 months salary Requirements: Experience in vehicle component testing and knowledge of industry regulations [13]. - **Position: Sales Engineer at Shanghai Zhuoguang** Salary: 6k-12k, 13 months salary Requirements: Relevant degree and 1-3 years of sales experience in precision instruments [15]. - **Position: Microcontroller Engineer at Shanghai Bang'an** Salary: 8k-10k, 12 months salary Requirements: Experience in MCU development and familiarity with common communication protocols [17].

Core Viewpoint - LabTech Holdings, Inc. plans to transfer 4,145,454 shares of Beijing Laibotai Technology Co., Ltd. to Qingdao Innovation Investment Co., Ltd. at a price of 27.50 CNY per share, representing 6.15% of the total shares, without changing the controlling shareholder or actual controller of the company [2][22]. Summary by Sections Agreement Overview - The transfer agreement was signed on October 20, 2025, with LabTech Holdings transferring 4,145,454 shares at a price of 27.50 CNY per share [4][6]. - After the transfer, Qingdao Innovation Investment will hold 6.15% of the company's total shares [2][4]. Shareholding Situation Before and After Transfer - LabTech Holdings, as a major shareholder, will see its shareholding decrease from 57.48% to 51.33% after the transfer [31][36]. Purpose and Background of the Transfer - The transfer aims to optimize the shareholder structure and introduce investors who recognize the company's development plans and long-term investment value [6][29]. Payment Terms - The total payment for the shares is 113,999,985 CNY, with specific payment schedules outlined, including an initial payment of 30% within five trading days after the transfer confirmation [8][38]. Compliance and Approval - The transfer requires compliance confirmation from the Shanghai Stock Exchange and registration with the China Securities Depository and Clearing Corporation [3][7]. Restrictions on Shareholding - The acquiring party, Qingdao Innovation Investment, commits not to reduce its shareholding within 12 months after the transfer [22][42].

【莱伯泰科股东转让6.15%股份，青岛创新投资入局】20日，莱伯泰科公告透露，持股5%以上股东 LabTechHoldings与青岛创新投资签订《股份转让协议》。LabTechHoldings拟以27.50元/股的价格，向青 岛创新投资转让4,145,454股无限售流通股，占公司股份总数的6.15%。 转让完成后，青岛创新投资将持 有4,145,454股，占比6.15%，成为持股5%以上股东。此次协议转让不会使公司控股股东、实际控制人发 生变更。 本文由 AI 算法生成，仅作参考，不涉投资建议，使用风险自担 扫码查看原文 【莱伯泰科股东转让6.15%股份,青岛创新投资入 局】20日,莱伯泰科公告透露,持股5%以上股东 LabTechHoldings与青岛创新投资签订《股份转让 协议》。LabTechHoldings 拟以27.50元/股的价 格,向青岛创新投资转让4.145.454股无限售流通 股,占公司股份总数的6.15%。转让完成后,青岛 创新投资将持有4,145,454股,占比6.15%,成为持 股5%以上股东。此次协议转让不会使公司控股股 东、实际控制人发生变更。 本文由 Al 算法生成,仅作参考,不 ...

Core Viewpoint - LabTech Holdings intends to transfer 4.1455 million shares of Leibotech (688056.SH) to Qingdao Innovation Investment at a price of 27.50 CNY per share, representing 6.15% of the company's total shares [1] Group 1 - The share transfer agreement was signed on October 20, 2025, between LabTech Holdings and Qingdao Innovation Investment [1] - After the completion of the transfer, Qingdao Innovation Investment will become a shareholder holding more than 5% of the company [1] - The transfer will not result in a change of the company's controlling shareholder or actual controller, nor will it trigger a mandatory bid or significantly impact the company's governance structure and ongoing operations [1]

Core Viewpoint - LabTech Holdings plans to transfer 4.1455 million shares of Leibotech (688056.SH) to Qingdao Innovation Investment at a price of 27.50 CNY per share, representing 6.15% of the company's total shares [1] Group 1 - The share transfer agreement was signed on October 20, 2025, between LabTech Holdings and Qingdao Innovation Investment [1] - After the transfer, Qingdao Innovation Investment will hold 4.1455 million shares, becoming a shareholder with over 5% ownership [1] - The transfer will not result in a change of the company's controlling shareholder or actual controller, nor will it trigger a mandatory bid or significantly impact the company's governance structure or ongoing operations [1]

北京莱伯泰科仪器股份有限公司 简式权益变动报告书（受让方） | 信息披露义务人： | 青岛市创新投资有限公司 | | --- | --- | | 住所及通讯地址： | 山东省青岛市崂山区苗岭路15号全球（青岛）创投风投中心2001 | | | 室 | | 股份变动性质： | 股份增加（协议转让） | 签署日期： 2025 年 10 月 20 日 1 上市公司名称： 北京莱伯泰科仪器股份有限公司 股票上市地点： 上海证券交易所 股票简称： 莱伯泰科 股票代码： 688056.SH 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"） 《上市公司收购管理办法》（以下简称"《收购管理办法》"）《公开发行证券 的公司信息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"《准 则 15 号》"）等相关法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人公司章程或内部规则的任何条款，或与之相冲突。 三、依据《证券法》《收购管理办法》《准则 15 号》的规定，本报告书已 全面覆盖信息披露义务人在北京莱伯 ...

北京莱伯泰科仪器股份有限公司 简式权益变动报告书（转让方） 信息披露义务人1： LabTech Holdings, Inc. 住所及通讯地址： 美国特拉华州纽卡斯尔县威明顿市橘子街1209号 信息披露义务人2： 北京莱伯泰科管理咨询有限公司 住所及通讯地址： 北京市朝阳区呼家楼（京广中心）11层商务单元1132 信息披露义务人3： 北京兢业诚成咨询服务有限公司 住所及通讯地址： 北京市顺义区空港工业区B区安庆大街6号 股份变动性质： 股份减少（协议转让） 签署日期：2025年10月20日 上市公司名称： 北京莱伯泰科仪器股份有限公司 股票上市地点： 上海证券交易所 股票简称： 莱伯泰科 股票代码： 688056.SH 信息披露义务人声明 一、信息披露义务人根据《中华人民共和国证券法》（以下简称"《证券 法》"）《上市公司收购管理办法》（以下简称"《收购管理办法》"）《公开发 行证券公司信息披露内容与格式准则第 15 号——权益变动报告书》（以下简称 "《准则 15 号》"）等相关的法律、法规及规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人公司章程 ...

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-036 关于公司持股 5%以上股东协议转让部分股份 暨权益变动的提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 10 月 20 日，北京莱伯泰科仪器股份有限公司（以下简称"莱伯 泰科"或"公司"或"目标公司"）持股 5%以上股东 LabTech Holdings, Inc. （以下简称"LabTech Holdings"或"转让方"）与青岛市创新投资有限公司（以 下简称"青岛创新投资"或"受让方"）共同签署了《股份转让协议》，LabTech Holdings 拟以 27.50 元/股的价格向青岛创新投资转让其持有的公司无限售流通 股 4,145,454 股，占公司股份总数的 6.15%。本次协议转让完成后，青岛创新投 资将持有公司股份 4,145,454 股，占公司股份总数的 6.15%，成为公司持股 5% 以上股东。 本次协议转让不会导致公司控股股东、实际控制人发生变更，不触及要 约收购，不会对公司治理结构及持 ...